INTEGRATED BIOPHARMA INC financial data

Symbol
INBP on OTC
Location
Hillside, NJ
Fiscal year end
30 June
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 384% % 34%
Quick Ratio 209% % 14%
Debt-to-equity 26% % -32%
Return On Equity 3% % 47%
Return On Assets 3% % 61%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31,059,610 shares 3.2%
Common Stock, Shares, Outstanding 31,059,610 shares 3.1%
Entity Public Float $3,111,877 USD -7.6%
Common Stock, Value, Issued $62,000 USD 3.3%
Weighted Average Number of Shares Outstanding, Basic 31,059,610 shares 3.2%
Weighted Average Number of Shares Outstanding, Diluted 31,421,338 shares 2.5%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) $1,693,000 USD 113%
Nonoperating Income (Expense) $39,000 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $1,754,000 USD 114%
Income Tax Expense (Benefit) $1,082,000 USD 179%
Net Income (Loss) Attributable to Parent $672,000 USD 56%
Earnings Per Share, Basic 0 USD/shares 100%
Earnings Per Share, Diluted 0 USD/shares 100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,732,000 USD 108%
Accounts Receivable, after Allowance for Credit Loss, Current $3,983,000 USD -9.2%
Inventory, Net $10,469,000 USD -6.7%
Other Assets, Current $440,000 USD 1.9%
Assets, Current $19,624,000 USD 7.2%
Deferred Income Tax Assets, Net $3,269,000 USD -26%
Property, Plant and Equipment, Net $1,819,000 USD -1.8%
Operating Lease, Right-of-Use Asset $612,000 USD -61%
Assets $25,540,000 USD -2.5%
Accounts Payable, Current $2,800,000 USD 1.3%
Liabilities, Current $4,764,000 USD -21%
Operating Lease, Liability, Noncurrent $183,000 USD -70%
Liabilities $5,051,000 USD -24%
Retained Earnings (Accumulated Deficit) $31,296,000 USD 2.1%
Stockholders' Equity Attributable to Parent $20,489,000 USD 4.8%
Liabilities and Equity $25,540,000 USD -2.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,301,000 USD 98%
Net Cash Provided by (Used in) Financing Activities $11,000 USD -57%
Net Cash Provided by (Used in) Investing Activities $173,000 USD -209%
Common Stock, Shares Authorized 50,000,000 shares 0%
Common Stock, Shares, Issued 31,094,510 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,117,000 USD 88%
Interest Paid, Excluding Capitalized Interest, Operating Activities $2,000 USD -83%
Deferred Tax Assets, Valuation Allowance $1,776,000 USD 40%
Operating Lease, Liability $1,323,000 USD
Depreciation $310,000 USD -1.6%
Payments to Acquire Property, Plant, and Equipment $173,000 USD 209%
Lessee, Operating Lease, Liability, to be Paid $1,400,000 USD
Property, Plant and Equipment, Gross $10,086,000 USD 2.2%
Operating Lease, Liability, Current $429,000 USD -55%
Lessee, Operating Lease, Liability, to be Paid, Year Two $169,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $661,000 USD
Deferred Income Tax Expense (Benefit) $68,000 USD -65%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $77,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $64,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $4,367,000 USD -13%
Deferred Federal Income Tax Expense (Benefit) $1,247,000 USD 305%
Operating Lease, Payments $254,000 USD -4.5%
Additional Paid in Capital $51,822,000 USD 0.51%
Depreciation, Depletion and Amortization $77,000 USD -9.4%
Deferred State and Local Income Tax Expense (Benefit) $183,000 USD -473%
Interest Expense $52,000 USD 0%